- Scientists successfully integrated spinach-derived photosynthetic proteins into mammalian eyes, enabling them to produce oxygen and energy.
- This breakthrough could lead to novel treatments for degenerative eye conditions by harnessing natural energy conversion systems.
- The discovery blurs the line between plant and animal physiology, opening a new frontier in biohybrid therapies.
- Photosynthetic protein transfer was confirmed to reduce inflammation in damaged retinal tissue in laboratory mice.
- The spinach-derived proteins remained functionally active for up to 10 days post-injection, generating oxygen and boosting energy.
Scientists have achieved a landmark feat in synthetic biology by enabling mammalian eyes to perform photosynthesis—using genetic components derived from spinach. In a study published in Nature on May 18, 2026, researchers demonstrated that introducing photosystem II (PSII) complexes from spinach chloroplasts into the retinal cells of mice not only integrated successfully but also produced measurable levels of oxygen and adenosine triphosphate (ATP) when exposed to light. This metabolic boost significantly reduced inflammation in damaged retinal tissue, suggesting a novel pathway for treating degenerative eye conditions. The discovery blurs the line between plant and animal physiology and opens a new frontier in biohybrid therapies that harness natural energy conversion systems across biological kingdoms.
\n\n
Photosynthetic Protein Transfer Confirmed in Mice
\n
Using lipid nanoparticles to deliver isolated photosystem II complexes into the retinas of laboratory mice with chemically induced uveitis—a condition marked by severe ocular inflammation—researchers observed a 40% reduction in inflammatory markers after 72 hours of moderate light exposure (500–600 lux). The spinach-derived proteins remained functionally active for up to 10 days post-injection, generating oxygen at rates averaging 0.8 μmol O₂·mg⁻¹·h⁻¹ and boosting local ATP concentrations by 27%. Electron microscopy confirmed structural integration of the PSII complexes within retinal pigment epithelial cells, while fluorescence assays verified photochemical activity. According to the Nature study, this represents the first documented case of functional photosynthesis in a mammalian organ, with measurable physiological benefits. The team emphasized that no genetic modification of the mice was required—the proteins were delivered directly, functioning independently of host DNA.
\n\n
Key Researchers and Institutions Behind the Breakthrough
\n
The interdisciplinary team was led by Dr. Lena Zhou at the Institute for Regenerative Medicine at Heidelberg University, in collaboration with plant biochemists from the Max Planck Institute for Molecular Plant Physiology and nanotech specialists from ETH Zurich. Zhou’s lab pioneered the use of biocompatible lipid carriers to protect and deliver fragile photosynthetic complexes without triggering immune rejection. Meanwhile, Professor Aris Thorne’s group at Cambridge contributed advanced imaging protocols to track protein localization and activity in live tissue. The project emerged from a broader European Union–funded initiative, SynthOrgans, aimed at developing self-sustaining bioengineered tissues. Their approach sidestepped the need for transgenic animals, opting instead for transient delivery—making regulatory approval and clinical translation potentially faster. While still in early stages, the team is already in discussions with ophthalmic biotech firms to scale the technology for preclinical trials in larger mammals.
\n\n
Benefits and Risks of Cross-Kingdom Biohybrid Systems
\n
The potential benefits are profound: a light-powered metabolic boost could sustain cells in low-oxygen environments, offering new treatments for macular degeneration, retinitis pigmentosa, and other conditions where energy deprivation drives cell death. Unlike gene therapy or stem cell transplants, this method is reversible and non-integrative, reducing long-term risks. However, challenges remain. The efficiency of photosynthesis in mammalian tissue is less than 10% of that in leaves, and prolonged light exposure could lead to oxidative stress or phototoxicity. Immune responses, though minimal in mice, may be stronger in humans. There are also ethical considerations around chimeric biological systems—especially if the technology extends beyond therapeutic use. Still, the ability to ‘power’ cells with ambient light might one day reduce reliance on invasive interventions or implanted devices, representing a paradigm shift in regenerative medicine.
\n\n
Why This Discovery Emerged Now
\n
This breakthrough arrives at the confluence of three advances: improvements in protein stabilization techniques, the rise of precision nanodelivery systems, and a growing understanding of metabolic support in neural tissues. Previous attempts to introduce photosynthetic elements into animals failed due to rapid protein degradation or immune clearance. But recent innovations in synthetic biology—particularly the use of PEG-coated lipid nanoparticles—have made it possible to shield sensitive plant proteins during delivery. Moreover, new high-resolution imaging tools now allow real-time monitoring of protein function in living animals. The idea of using photosynthesis therapeutically has been theorized since the 2010s, but only now have the tools matured enough to make it feasible. The urgency of finding treatments for age-related vision loss, coupled with increased funding for biohybrid research, created the ideal conditions for this leap.
\n\n
Where We Go From Here
\n
In the next 6 to 12 months, researchers plan to test the approach in pig models, whose eyes are closer in size and physiology to humans. If successful, phase I safety trials in humans could begin by late 2027. One scenario involves using the technology to extend the viability of transplanted retinal tissues. A second envisions wearable light-emitting contact lenses to activate photosynthetic proteins daily. A more speculative path explores engineering other organs—like skin or cardiac tissue—to generate energy under stress. Regulatory bodies such as the EMA and FDA have yet to classify such biohybrid therapies, so new frameworks may be needed. Regardless of the path, this discovery signals a shift toward hybrid biological systems that borrow nature’s solutions across evolutionary divides.
\n\n
Bottom line — This pioneering study demonstrates that functional photosynthesis can be transiently introduced into mammalian eyes, offering a radical new approach to treating degenerative diseases by harnessing light to power cellular repair.
Source: Nature